Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
OLFM4 was originally cloned from human myeloblasts and found to be selectively expressed in inflammed colonic epithelium. Additionally we are shipping Olfactomedin 4 Antibodies (68) and Olfactomedin 4 Proteins (13) and many more products for this protein.
Showing 10 out of 33 products:
Human OLFM4 ELISA Kit for Sandwich ELISA - ABIN415153
Makawita, Smith, Batruch, Zheng, Rückert, Grützmann, Pilarsky, Gallinger, Diamandis: Integrated proteomic profiling of cell line conditioned media and pancreatic juice for the identification of pancreatic cancer biomarkers. in Molecular & cellular proteomics : MCP 2011
Show all 3 references for ABIN415153
Olfactomedin-4 identifies a subpopulation of neutrophils in patients with septic shock, and those with a high percentage of olfactomedin-4+ neutrophils are at higher risk for greater organ failure burden and death. Olfactomedin-4 might serve as a marker of a pathogenic neutrophil subset in patients with septic shock
OLFM4 is proved to as a functional target for miR (show MLXIP ELISA Kits)-590.
Olfactomedin 4 is a novel tumor marker for triple-negative breast cancer for predicting and prognosis.
OLFM4 is downregulated by miR (show MLXIP ELISA Kits)-486-5p, which contributes to ovarian cancer tumorigenesis. Conversely, estrogen receptor (show ESR1 ELISA Kits) signaling downregulates miR (show MLXIP ELISA Kits)-486-5p and upregulates OLFM4 expression, slowing the development and progression of ovarian cancer.
Data show that olfactomedin 4 (OLFM4) is highly expressed in proliferating benign epithelial cells and in some carcinoma cells.
olfactomedin 4 appears to play a critical role in regulating progression of prostate cancer, and has potential as a new biomarker for prostate cancer.
Study demonstrates that epigenetic silencing of OLFM4 enhances gastric cancer cell invasion via activation of FAK (show PTK2 ELISA Kits) signaling.
suppression of OLFM4 expression may be a promising strategy in the development of novel cancer therapeutic drugs
Patients with an OLFM4 gene expression level above -7.5 were 6 times more likely to develop severe disease, after correction for age at hospitalization and gestational age.
Using a human vaginal epithelial cell line, the expression of mucin (show SLC13A2 ELISA Kits) 5 subtype B and olfactomedin-4 were down-regulated in response to N9, suggesting these markers could apply to humans
OLFM4 may function as a tumor suppressor and an anti-metastatic gene during tumor progression
Olfm4 deletion can successfully enhance immune defense against S. aureus, but not A. fumigatus, in chronic granulomatous disease mice.
OLFM4 exerts considerable influence on the host defense against H. pylori infection acting through NOD1 (show NOD1 ELISA Kits) and NOD2 (show NOD2 ELISA Kits) mediated NF-kappaB (show NFKB1 ELISA Kits) activation and subsequent cytokines and chemokines production, which in turn inhibit host immune response.
This gene was originally cloned from human myeloblasts and found to be selectively expressed in inflammed colonic epithelium. This gene encodes a member of the olfactomedin family. The encoded protein is an antiapoptotic factor that promotes tumor growth and is an extracellular matrix glycoprotein that facilitates cell adhesion.
, G-CSF-stimulated clone 1 protein
, antiapoptotic protein GW112
, PU.1 difference product 4